ExIST Study of LY2157299 (Galunisertib) in Rectal Cancer

NCT02688712 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Rectal Adenocarcinoma

Interventions

DRUG: LY2157299
DRUG: Capecitabine
DRUG: Fluorouracil
PROCEDURE: Tumor specific mesorectal excision

Sponsor

Providence Health & Services

Collaborators

[object Object]